EMERYVILLE, Calif., Feb. 6 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) today announced that it will present at the BIO CEO & Investor Conference on Wednesday, February 13, at 11:00 a.m. Eastern Time. Interested parties may access a live webcast of the presentation at: http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=ONXX&item_id=1752428 It is recommended that listeners log on 15 minutes early in order to register and download any necessary software. For those unable to listen to the live webcast, a recorded replay of the presentation will be available within 24 hours of the completion of the presentation through March 13, 2008.
Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer by changing the way cancer is treated(TM). The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar(R) (sorafenib) tablets, a small molecule drug. Nexavar is currently approved for the treatment of advanced kidney cancer and for the treatment of liver cancer. Additionally, Nexavar is being investigated in several ongoing trials in non-small cell lung cancer, melanoma, breast cancer, and other tumor types. For more information about Onyx, visit the company's website at: http://www.onyx-pharm.com/.
Nexavar(R) (sorafenib) tablets is a registered trademark of Bayer Pharmaceuticals Corporation. DATASOURCE: Onyx Pharmaceuticals, Inc.
CONTACT: Kim Jeger of Onyx Pharmaceuticals, Inc., +1-510-597-6330 Web site: http://www.onyx-pharm.com/
|